secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001213900-25-054961
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Orphan Drug Designation to CERo's CER-1236 for AML treatment
-----------------------------------------------------------------------

- FDA Orphan Drug Designation granted to CER-1236 for acute myeloid leukemia (AML).
- CER-1236 is an engineered T cell therapy leveraging phagocytic mechanisms; currently in Phase 1 trial.
- ODD qualifies CERo for 7-year marketing exclusivity, FDA trial assistance, and fee exemptions.
- AML is a life-threatening condition affecting ≤200,000 US patients annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025054961/0001213900-25-054961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025054961/ea0245971-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-054961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer